AI assistant
va-Q-tec AG — Earnings Release 2021
Mar 29, 2022
459_ip_2022-03-29_3b84a7cf-ba06-41fe-a86e-0c68942fc586.pdf
Earnings Release
Open in viewerOpens in your device viewer
va-Q-tec FY 2021 Earnings Release Presentation
29th March 2022
VQT with outstanding FY 2021 figures
EBITDA +64% to 18,7 Mio. EUR (FY 2020: 11,4 Mio. EUR); EBIT 5,0 Mio. EUR (FY 2020: -0,9 Mio. EUR) Systems revenue +86% YoY to 36,4 Mio. EUR (FY 2020: 19,5 Mio. EUR) va-Q-tec solutions generated high international Excellent growth performance: Revenue +44% to 104,1 Mio. EUR (FY 2020: 72,1 Mio. EUR) + + + +
acknowledgment enabling the Corona vaccine distribution

Group revenues grew by 44%

Almost tripled revenue since IPO in 2016



EBITDA and EBIT with strong improvement EBITDA and EBIT
Group EBIT In Mio. EUR
All margins on revenues
Group EBT In Mio. EUR
Group EBITDA
In Mio. EUR
Breakdown by cost position

6
| FY 21 In Mio. EUR |
FY 20 In Mio. EUR |
Difference in % |
||
|---|---|---|---|---|
| Revenue | 104,063 | 72,106 | 44 | |
| Total income | 122,531 | 84,132 | 46 | |
| Cost of Materials and Services | -50,754 | -32,751 | 55 | Incl. temp workers for temporary capacity expansion |
| Gross profit | 71,777 59% |
51,381 61% |
40 | |
| Personnel expenses | -33,082 27% |
-26,111 31% |
27 | Improved ratio |
| Other operating expense | -19,996 16% |
-13,870 16% |
44 | |
| EBITDA | 18,699 15% |
11,400 14% |
64 | |
| Depreciation & amortization | -13,655 | -12,299 | 11 | |
| EBIT | 5,044 | -900 | Positive EBIT | |
| Financial result | -2,246 | -1,259 | ||
| EBT | 2,798 | -1,511 | ||
| Income taxes | -636 | 77 | First tax payment | |
| Net income (EAT) | 2,162 | -1,434 | Positive EAT |
Cash flow summary
Operating CF before WC strongly improved

| In Mio. EUR | FY 21 | FY 20 | Comments |
|---|---|---|---|
| Operating cash flow before changes in Working Capital |
13,3 | 6,7 | development, +99% yoy |
| Operating cash flow | 3,3 | 7,4 | and for intl, subsidiaries |
| Investing cash flow | -24,2 | -11,8 | |
| Thereof payments for investments in property, plant and equipment* |
-22,1 | -11,4 | term growth |
| Financing cash flow | 13,6 | 14,1 | to negative FCF |
| Net change in cash | -7,3 | 9,6 | |
| Free cash flow | -20,9 | -4,4 | in 2022 |
| Cash and cash equivalents | 9,8 | 17,1 | Available lines + cash = |
*c. 80% growth CAPEX
Comments
- Operating CF before WC with a strong development, +99% yoy
- WC build-up mainly for business in Q3/Q4 and for intl, subsidiaries
- Accelerated investing CF to ramp-up capacity for CoVid-19 logistics and midterm growth
- Growth CapEx (c. 80% of 2021 CapEx plus WC for extraordinary business growth led to negative FCF
- Fully on track to achieve FCF break-even in 2022
15.3 Mio. EUR
No Goodwill, Net Debt excl. mortgage loans: 2.0x 2021 EBITDA
Solid equity ratio of 36%, no goodwill


Profitable Growth aspired Short-term outlook

| Guidance FY22e | Assumptions | ||
|---|---|---|---|
| Revenues | 115-122 Mio. EUR | • With ~75% Healthcare revenues in 2022E, stable business assumed • No major negative impact from geopolitical tensions • Supply chain constraints and increased inflation considered to some extent |
|
| EBITDA | Growing – stable Margins |

Mid-term targets for 2025 – Strong Growth continues
160-180 Mio. EUR Revenues - 22-26% Margin
| Strategic and Financial KPIs | ||||
|---|---|---|---|---|
| 2021 | 2025 | |||
| Revenues | 104,1 Mio. EUR | 160-180 Mio. EUR (Implied 2020-2025 CAGR: ~20%) |
||
| EBITDA Margin | 18% | 22-26% | ||
| Main | TempChain +++ (Systems & Services) |
|||
| Growth Drivers | Thermal Energy Efficiency ++ (Products) |

Our path to 2025
2021 2025 • Efficiency gains in operations, logistics and purchasing • Scaling effects for IT, corporate functions and personnel • Marketing & Brand power Operating Leverage & Excellence Operating and strategic levers to achieve 2025 goals • Novel healthcare areas (mRNA, Cell & Gene) • Food & consumer products • Construction • Mobility Contribution of new markets Sales Mix and margin • Increasing share of Services • Sales of high-margin Thermal Energy Applications • Broadened global footprint, e.g. enhanced Footprint in the US High Margin Sales & International BizDev 160-180 Mio. EUR Revenues 22-26% EBITDA margin 104,1 Mio. EUR Revenues 18% EBITDA margin
Thank you for your attention!
va-Q-tec AG
Alfred-Nobel-Straße 33 97080 Würzburg Tel,: +49 931 35942-1616 Fax: +49 931 35942-0 IR@va-Q-tec,com
TICKER
Symbol: VQT Bloomberg: VQT:GY Reuters: VQTG:DE ISIN: DE0006636681 WKN: 663668
Revenues by business line
Strong growth across the board


• Continued good growth in H1, Q4 with strong comparison basis and frontloading effect
• Explosive growth in Q3 & Q4, highest Corona share (va-Q-pal)
• Accelerating momentum in Q3 & Q4
Group revenues grew by 44%


Revenue Shares TempChain 74% Corona-related Business 2% Revenue Shares TempChain 78% Corona-related Business 23% FY 2020 72,1 Mio. EUR FY 2021 104,1 Mio. EUR +44% Services Systems Products 36,4 44,1 Services 22,0 Systems Products 18,3 19,5 32,7 2020 2021
14
Consolidated Income Statement

| In Mio. EUR | FY 2021 | in % | FY 2020 | in % | Difference in % |
|---|---|---|---|---|---|
| Revenue | 104,063 | 100,0% | 72,106 | 100,0% | 44,32 |
| Change in inventory | 2,846 | 978 | 191,00 | ||
| Own work capitalized (primarily building of own container fleet) | 11,328 | 6,379 | 77,58 | ||
| Other operating income |
4,294 | 4,669 | -8,03 | ||
| Total income | 122,531 | 84,132 | 45,64 | ||
| COGS | -50,754 | -32,751 | 54,97 | ||
| Gross profit | 71,777 | 69% | 51,381 | 71% | 39,70 |
| Personnel expenses |
-33,082 | -26,111 | 26,70 | ||
| Other operating expense |
-19,996 | -13,871 | 44,16 | ||
| EBITDA | 18,699 | 18% | 11,399 | 16% | 64,04 |
| Depreciation & amortization |
-13,656 | -12,299 | 11,03 | ||
| EBIT | 5,044 | 5% | -900 | -1% | -660,44 |
| Valuation and result from equity investments | 0 | 0 | 0,00 | ||
| Financial result | -2,246 | -1,259 | 78,40 | ||
| EBT | 2,798 | 3% | -1,512 | -2% | -285,05 |
| Income taxes | -636 | 77 | -925,97 | ||
| Net income | 2,162 | 2% | -1,435 | -2% | -250,66 |

Consolidated Balance Sheet
| In Mio. EUR | 31.12.2021 | 31.12.2020 | Difference in % |
|---|---|---|---|
| Cash & cash equivalents | 9,810 | 17,134 | -42,75 |
| Trade receivables | 12,432 | 6,532 | +90,32 |
| Inventories | 18,469 | 11,615 | +59,01 |
| Other current assets | 7,570 | 2,479 | +205,4 |
| Total current assets | 48,281 | 37,760 | +27,86 |
| Tangible fixed assets | 82,649 | 69,636 | +18,69 |
| Intangible assets | 4,273 | 2,955 | +44,60 |
| Other noncurrent assets | 9,962 | 8,717 | +14,3 |
| Total noncurrent assets | 96,884 | 81,308 | +19,16 |
| Total assets | 145,165 | 119,068 | +21,92 |
| Short-term financial liabilities |
31,756 | 16,605 | +191,2 |
| Other short-term liabilities |
5,437 | 4,595 | +18,32 |
| Long-term financial liabilities |
51,697 | 51,187 | +01,0 |
| Other long-term liabilities |
4,628 | 5,425 | -14,69 |
| Total provisions and liabilities | 93,518 | 77,812 | +20,2 |
| Total equity | 51,647 | 41,256 | +25,19 |
| Total liabilities and equity | 145,165 | 119,068 | +21,92 |
Consolidated Cash Flow Statement

| In Mio. EUR | FY 2021 | FY 2020 | Difference in % |
|---|---|---|---|
| Cash flow from operating activities before change in NWC | 13,333 | 6,745 | +97,7 |
| Cash flow from operating activities after change in NWC | 3,280 | 7,405 | -55,7 |
| Cash flow from investing activities | -24,222 | -11,819 | +104,9 |
| Free cash flow | -20,942 | -4,414 | -374,4 |
| Cash flow from financing activities | 13,571 | 14,124 | -03,9 |
| Effects of exchange rate changes | 47 | -66 | |
| Net cash inflow/outflow | -7,324 | 9,644 | |
| Cash and cash equivalents per start of period | 17,134 | 7,490 | +128,8 |
| Cash and cash equivalents per end of period | 9,810 | 17,134 | -42,8 |